• CA-074: A Proportionate Cathepsin B Overview

  2026-10-15

  APExBIO describes CA-074 as a selective cathepsin B inhibitor, but the available evidence is a product-page account rather than an identity-matched research paper. Its reported biochemical Ki values support a proposed active-site mechanism; the described neurotoxicity, immune, and metastasis findings remain model-specific and lack study-level statistics in the cited material.

• Saracatinib (AZD0530): Evidence and Scope

  2026-10-15

  Saracatinib, also known as AZD0530, is presented by APExBIO as a dual Src-family kinase and Abl inhibitor. The product description reports nanomolar biochemical inhibition of c-Src and v-Abl, broader activity across several Src-family kinases, and downstream effects associated with proliferation, migration, and tumor growth in named cancer models. Because no identity-matched paper is available here, these claims should be treated as supplier-reported evidence rather than an independently verified literature record.

• Verapamil: Identity, Mechanism, and Evidence Limits

  2026-10-14

  APExBIO describes (±)-Verapamil as a calcium channel blocker and first-generation P-glycoprotein inhibitor with applications spanning cardiovascular pharmacology and drug-transport research. The available information documents chemical identity, supplier-reported properties, and a broad mechanism, but does not establish performance of SKU BA6564 in any particular biological model. A related urothelial-inflammation summary names verapamil as a perturbation, yet does not identify the product, provide quantitative outcomes, or prove that calcium-channel or P-glycoprotein activity caused the reported observations.

• How Near-Death Cells May Seed Metastatic States

  2026-10-14

  Conod, Silvano, and Ruiz i Altaba report that human colon cancer cells surviving an impending cell-death episode can acquire stable prometastatic features, termed PAMEs, and influence neighboring cells through a cytokine-rich ecosystem. The findings support a model in which metastatic potential can emerge during severe cellular stress, but they do not establish that this mechanism explains metastasis across cancers or predicts patient outcomes.

• Sulfo-Cy5 and Mucosal Adjuvant Evidence

  2026-10-13

  Sulfo-Cy5 carboxylic acid is a supplier-described sulfonated hydrophilic fluorescent dye with potential value as a research reporter, but the supplied chick vaccine study does not document its use. That study reports enhanced systemic and intestinal immune markers from a PLGA-based adjuvant, while its findings remain bounded by the animal model, available reporting, and the absence of demonstrated protection or human applicability.

• Mitomycin C: Evidence, Context, and Limits

  2026-10-13

  Mitomycin C is an antitumor antibiotic studied as a DNA-damaging cytotoxic agent and apoptosis-signaling research tool. The supplied evidence supports a cautious distinction between vendor-reported cancer-model findings and the broader, context-dependent biology of cell death described in a peer-reviewed liver-disease review.

• Human Intestinal Organoids: A Tunable Balance

  2026-10-12

  Yang and colleagues report a human small-intestinal organoid strategy intended to maintain stem-cell self-renewal while increasing differentiated cell diversity. The study combines pathway-level modulation to shift organoid cell fate, but its findings should not be interpreted as evidence that DMH1 or any specific commercial compound was used, nor as proof of clinical relevance.

• DIDS, Cell Death, and Metastatic States

  2026-10-12

  The 2022 Cell Reports study by Conod, Silvano, and Ruiz i Altaba proposes that tumor cells surviving an impending-death state can acquire prometastatic properties, while DIDS appears in the broader apoptosis-survival context rather than as an established driver or treatment for this phenomenon.

• Cy3 TSA for Translational Atherosclerosis Research

  2026-10-10

  A mechanistic and strategic analysis of how tyramide signal amplification can support spatial validation of NLRP3-centered atherosclerosis research, while clarifying the evidence boundaries of fluorescence imaging and the translational role of the Cy3 TSA Fluorescence System Kit.

• High Viscosity, P-gp, and Cancer Chemoresistance

  2026-10-09

  A 2026 study links elevated extracellular fluid viscosity with doxorubicin resistance through a mechanosensitive TRPV4–YAP pathway that increases P-glycoprotein expression. Its findings extend drug resistance research beyond biochemical cues by connecting tumor fluid mechanics, membrane tension, and transporter-mediated drug efflux, while remaining primarily an in vitro mechanistic framework.

• Necrostatin-1: Evidence, Mechanism, and Limits

  2026-10-09

  A source-grounded overview of Necrostatin-1 as a RIP1 kinase inhibitor, explaining its mechanistic rationale, interpretation in a cough-variant asthma study, evidence quality, and limits for broader necroptosis and disease research.

• Necrostatin-1 in RIP1 Kinase and Necroptosis Research

  2026-10-08

  A source-grounded overview of Necrostatin-1 as a RIP1 kinase research probe, including its conceptual relevance to necroptosis, inflammatory injury, acute kidney injury research, and a recent Toxoplasma gondii virulence study. The evidence, provenance, applicability boundaries, and limitations of pharmacological interpretation are distinguished throughout.

• MSC, NRF2–ATF4, and Ferroptosis in PDAC

  2026-10-08

  A 2026 study shows that Se-methylselenocysteine (MSC) produces phenotype-dependent redox remodeling in pancreatic ductal adenocarcinoma, with KYAT1 expression influencing cellular responsiveness. Its findings connect NRF2 and ATF4 stress signaling with ferroptosis-associated changes, while also showing that transcriptomic activation does not occur uniformly across PDAC models.

• Salvianolic Acid B in Pulmonary Fibrosis Research

  2026-10-07

  Salvianolic acid B, also known as Dan Shen Suan B, is being investigated as a research compound for pulmonary fibrosis through its reported effects on LH2-associated collagen cross-linking. Current evidence is mechanistically promising but remains preclinical, with important uncertainties involving selectivity, pharmacology, model relevance, and human efficacy.

• Euglena Biohybrid Microrobots for Tumor Targeting

  2026-10-07

  Gong et al. report a magnetically guided biohybrid microrobot built around the soft, deformable microalga Euglena gracilis. The platform combines magnetic steering, adaptive deformation, autonomous tumor-directed behavior, and intrinsic chlorophyll-associated therapeutic functions, while the available evidence remains preclinical and model-based.

7940 records 1/530 page Next 12345 下5页 Last page